Deciphera Pharmaceuticals Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 400

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $2.4B

Deciphera Pharmaceuticals General Information

Description

Developer of kinase-inhibiting drugs designed to treat cancer and immunological diseases.The company offers a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors, enabling patients living with cancer to access transformative therapies that aim to improve their quality of life.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 200 Smith Street
  • Waltham, MA 02451
  • United States
+1 (781)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Other Pharmaceuticals and Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • 200 Smith Street
  • Waltham, MA 02451
  • United States
+1 (781)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Deciphera Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 11-Jun-2024 $2.4B Completed Generating Revenue
9. 2PO 24-Jan-2023 Completed Generating Revenue
8. Secondary Transaction - Private 12-Aug-2020 Completed Generating Revenue
7. Secondary Transaction - Open Market Completed Clinical Trials - Phase 1
6. Secondary Transaction - Open Market 13-Feb-2020 Completed Clinical Trials - Phase 1
5. 2PO 11-Jun-2018 Completed Clinical Trials - Phase 1
4. IPO 28-Sep-2017 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series C) 05-Jun-2017 Completed Generating Revenue
2. Later Stage VC (Series B) 05-Jan-2016 $90M $90M Completed Generating Revenue
1. Grant 18-Jul-2011 $4.99M Completed Generating Revenue
To view Deciphera Pharmaceuticals’s complete valuation and funding history, request access »

Deciphera Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of kinase-inhibiting drugs designed to treat cancer and immunological diseases.The company offers a diverse pi
Drug Discovery
Waltham, MA
400 As of 2025

Cambridge, MA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Deciphera Pharmaceuticals Competitors (84)

One of Deciphera Pharmaceuticals’s 84 competitors is Blueprint Medicines, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Blueprint Medicines Formerly VC-backed Cambridge, MA
Aura Biosciences Formerly VC-backed Boston, MA
Day One Biopharmaceuticals Formerly VC-backed Brisbane, CA
Ability Pharma Private Equity-Backed Cerdanyola, Spain
OncoResponse Venture Capital-Backed Houston, TX
You’re viewing 5 of 84 competitors. Get the full list »

Deciphera Pharmaceuticals Patents

Deciphera Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026212999-A1 Processes for making ulk inhibitors Pending 31-Mar-2025
WO-2026165163-A1 Cdk inhibitors and methods of use thereof Pending 30-Jan-2025
WO-2026136733-A1 Cdk inhibitors and methods of use thereof Pending 20-Dec-2024
WO-2026136890-A1 Formulations of ulk inhibitors Pending 20-Dec-2024
WO-2026136890-A9 Formulations of ulk inhibitors Pending 20-Dec-2024 A61K31/553
To view Deciphera Pharmaceuticals’s complete patent history, request access »

Deciphera Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Deciphera Pharmaceuticals Former Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Altamont Pharmaceutical Holdings Holding Company Minority
Brinker Capital Asset Manager Minority
Colorado Public Employees' Retirement Association Corporation Minority
Ensign Peak Advisors Corporation Minority
Frazier Healthcare Partners PE/Buyout Minority
You’re viewing 5 of 15 investors. Get the full list »

Deciphera Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated February, 28, 2025

25.41 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,766

Rank

Percentile

Pharmaceuticals

Industry

of 891

Rank

Percentile

Pharmaceuticals

Subindustry

of 394

Rank

Percentile

To view Deciphera Pharmaceuticals’s complete esg history, request access »

Deciphera Pharmaceuticals Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Redmile Deciphera Holdings San Francisco, CA 2019

Deciphera Pharmaceuticals FAQs

  • When was Deciphera Pharmaceuticals founded?

    Deciphera Pharmaceuticals was founded in 2003.

  • Where is Deciphera Pharmaceuticals headquartered?

    Deciphera Pharmaceuticals is headquartered in Waltham, MA.

  • What is the size of Deciphera Pharmaceuticals?

    Deciphera Pharmaceuticals has 400 total employees.

  • What industry is Deciphera Pharmaceuticals in?

    Deciphera Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Deciphera Pharmaceuticals a private or public company?

    Deciphera Pharmaceuticals is a Private company.

  • What is the current valuation of Deciphera Pharmaceuticals?

    The current valuation of Deciphera Pharmaceuticals is .

  • What is Deciphera Pharmaceuticals’s current revenue?

    The current revenue for Deciphera Pharmaceuticals is .

  • How much funding has Deciphera Pharmaceuticals raised over time?

    Deciphera Pharmaceuticals has raised $414M.

  • Who are Deciphera Pharmaceuticals’s investors?

    Altamont Pharmaceutical Holdings, Brinker Capital, Colorado Public Employees' Retirement Association, Ensign Peak Advisors, and Frazier Healthcare Partners are 5 of 15 investors who have invested in Deciphera Pharmaceuticals.

  • Who are Deciphera Pharmaceuticals’s competitors?

    Blueprint Medicines, Aura Biosciences, Day One Biopharmaceuticals, Ability Pharma, and OncoResponse are some of the 84 competitors of Deciphera Pharmaceuticals.

  • When was Deciphera Pharmaceuticals acquired?

    Deciphera Pharmaceuticals was acquired on 11-Jun-2024.

  • Who acquired Deciphera Pharmaceuticals?

    Deciphera Pharmaceuticals was acquired by ONO Pharmaceutical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process